Report cover image

CAR T-Cell Therapy Market Growth, Size, Trends Analysis- By Drug Type, By Indication, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Publisher SPER Market Research Pvt. Ltd.
Published Oct 24, 2024
Length 237 Pages
SKU # SPER19321806

Description

CAR T-Cell Therapy Market Growth, Size, Trends Analysis- By Drug Type, By Indication, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033


CAR T-Cell Therapy Market Introduction and Overview

According to SPER Market Research, ‘Global CAR T-Cell Therapy Market Size- By Drug Type, By Indication, By End User – Regional Outlook, Competitive Strategies and Segment Forecast to 2033’ states that the Global CAR T-Cell Therapy Market is estimated to reach USD 46.23 billion by 2033 with a CAGR of 28.78%.

One of the most innovative methods for treating cancer is CAR T-cell therapy. This novel immunotherapy fights cancer by utilizing the patient’s immune system. For patients who have not responded to traditional treatments for a variety of hematologic malignancies, such as various types of leukemia and lymphoma, CAR T-cell therapy has demonstrated exceptional potential as a game-changing therapeutic alternative.

In 2020, the COVID-19 pandemic slowed the development of CAR-T cell therapy. The poor diagnostic rate of blood cancer was mostly caused by a number of issues that beset the healthcare system throughout the epidemic. First, the pandemic reduced the frequency of routine medical checks and screenings because many clinics and hospitals delayed unnecessary testing and visits in an effort to reduce the risk of COVID-19 virus transmission.

Scope of the report:

Report Metric Details
Market size available for years 2020-2033
Base year considered 2023
Forecast period 2024-2033
Segments covered By Drug Type, By Indication, By End User
Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
Companies Covered Autolus Therapeutics, Bluebird Bio, Inc., Bristol-Myers Squibb, Caribou Biosciences, Inc., Cellectis, Celgene Corporation, Gilead Sciences, Inc., Intellia Therapeutics, Juno Therapeutics, Inc., Inc., Miltenyi Biotech, Novartis AG, Pfizer, Inc.

CAR T-Cell Therapy Market Segmentation:

By Drug Type: Based on the Drug Type, Global CAR T-Cell Therapy Market is segmented as; Axicabtage Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others.

By Indication: Based on the Indication, Global CAR T-Cell Therapy Market is segmented as; Lymphoma, Acute Lymphocytic Leukemia, Others.

By End User: Based on the End User, Global CAR T-Cell Therapy Market is segmented as; Hospitals, Cancer Treatment Centers.

By Region: This research also include data for North America, Europe, Asia-Pacific Middle East & Africa and South America.

Table of Contents

237 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global CAR T-Cell Therapy Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global CAR T-Cell Therapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global CAR T-Cell Therapy Market
7. Global CAR T-Cell Therapy Market, By Drug Type (USD Million) 2020-2033
7.1. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Drug Type, 2020-2026
7.2. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Drug Type, 2027-2033
7.3. Axicabtagene Ciloleucel
7.4. Tisagenlecleucel
7.5. Brexucabtagene Autoleucel
7.6. Others
8. Global CAR T-Cell Therapy Market, By Indication (USD Million) 2020-2033
8.1. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Indication, 2020-2026
8.2. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Indication, 2027-2033
8.3. Lymphoma
8.4. Acute Lymphocytic Leukemia
8.5. Others
9. Global CAR T-Cell Therapy Market, By End User (USD Million) 2020-2033
9.1. Global CAR T-Cell Therapy Market Size, Share and Forecast, By End User, 2020-2026
9.2. Global CAR T-Cell Therapy Market Size, Share and Forecast, By End User, 2027-2033
9.3. Hospitals
9.4. Cancer Treatment Centers
10. Global CAR T-Cell Therapy Market Forecast, 2020-2033 (USD Million)
10.1. Global CAR T-Cell Therapy Market Size and Market Share
11. Global CAR T-Cell Therapy Market, By Region, 2020-2033 (USD Million)
11.1. Global CAR T-Cell Therapy Market Size and Market Share By Region (2020-2026)
11.2. Global CAR T-Cell Therapy Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Qatar
11.5.4. South Africa
11.5.5. Egypt
11.5.6. Morocco
11.5.7. Nigeria
11.5.8. Rest of Middle-East and Africa
11.6. North America
11.6.1. Canada
11.6.2. Mexico
11.6.3. United States
11.7. Latin America
11.7.1. Argentina
11.7.2. Brazil
11.7.3. Rest of Latin America
12. Company Profile
12.1. Autolus Therapeutics
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Bluebird Bio, Inc.
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Bristol-Myers Squibb
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Caribou Biosciences, Inc.
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. Cellectis
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Celgene Corporation
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Celyad Oncology
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Cartesian Therapeutics, Inc.
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Gilead Sciences, Inc. (Kite Pharma Inc.)
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Intellia Therapeutics
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Juno Therapeutics, Inc.
12.11.1. Company details
12.11.2. Financial outlook
12.11.3. Product summary
12.11.4. Recent developments
12.12. Merck & Co., Inc.
12.12.1. Company details
12.12.2. Financial outlook
12.12.3. Product summary
12.12.4. Recent developments
12.13. Miltenyi Biotech
12.13.1. Company details
12.13.2. Financial outlook
12.13.3. Product summary
12.13.4. Recent developments
12.14. Novartis AG
12.14.1. Company details
12.14.2. Financial outlook
12.14.3. Product summary
12.14.4. Recent developments
12.15. Pfizer, Inc.
12.15.1. Company details
12.15.2. Financial outlook
12.15.3. Product summary
12.15.4. Recent developments
12.16. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us